BNP Paribas Exane Downgrades Organon & Co. (OGN) to Neutral Post Acquisition
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Sun Pharma signs Definitive Agreement to Acquire Organon
April 26, 2026 7:51 PM EDTOrganon stockholders to receive US$ 14.00 per share in cash
The deal values Organon at EV of US$ 11.75 billion
Combined Business leverages complementary portfolios and global scale for sustained longterm value creation
MUMBAI, India & JERSEY CITY, N.J.--(BUSINESS WIRE)-- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, Sun Pharma) and Organon & Co. (NYSE: OGN) (Organon) today... More
